Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 49.9 | 44.0 | 43.5 | 46.7 | 51.7 | 57.1 | 54.8 | 57.4 |
| Operating profit | $bn | 17.8 | 16.4 | ||||||
| Net profit | $bn | 8.1 | 24.0 | 7.0 | 14.9 | 11.9 | 14.6 | 12.7 | 17.2 |
| EPS reported | $ | 7.49 | 6.55 | ||||||
| Operating cashflow per share | $ | 10.34 | 9.49 | ||||||
| Capex per share | $ | 0.84 | 1.11 | ||||||
| FCF per share | $ | 9.51 | 8.38 | ||||||
| Free cash flow | $bn | 18.4 | 16.0 | ||||||
| Net debt | $bn | 23.5 | 41.4 | ||||||
| Book value equity | $bn | 46.1 | 41.7 | ||||||
| Book value per share | $ | 23.58 | 21.76 | ||||||
| Number of shares | m | 1,955 | 1,914 | ||||||
| DPS (TTM paid) | $ | 4.76 | 4.76 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 18.46 | 22.48 | ||||||
| P/B LTM | x | 5.81 | 6.55 | ||||||
| P/S LTM | x | 4.69 | 4.98 | ||||||
| P/FCF LTM | x | 14.54 | 17.08 | ||||||
| EV/EBITDA LTM | x | 12.26 | 14.26 | ||||||
| EV/Sales LTM | x | 5.14 | 5.74 | ||||||
| Earnings Yield LTM | % | 5.42% | 4.45% | ||||||
| FCF Yield | % | 6.88% | 5.86% | ||||||
| Quality | |||||||||
| ROE | % | 31.78% | 29.64% | ||||||
| ROIC | % | 16.17% | 13.38% | ||||||
| Operating margin | % | 31.15% | 29.86% | ||||||
| Gross margin | % | 75.02% | 74.29% | ||||||
| FCF/Sales | % | 32.27% | 29.16% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +27.60% | -4.52% | ||||||
| Sales Growth YoY | % | +10.45% | -0.73% | ||||||
| Net Income Growth YoY | % | +22.68% | -7.35% | ||||||
| FCF Growth | % | +33.53% | -11.49% | ||||||
| Operating Profit Growth | % | +22.35% | -1.95% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 3.06% | 3.35% | ||||||
| Dividend Growth | % | +20.17% | +20.17% | ||||||
| Payout Ratio | % | 55.93% | 72.91% | ||||||
| FCF/Debt | x | 0.50 | 0.33 | ||||||
| Net Debt/EBITDA | x | 1.07 | 1.88 | ||||||
| EBIT/Net interest | x | 14.38 | 11.88 | ||||||
| Net debt/market cap | % | 8.77% | 15.14% | ||||||
| Net debt/Equity | x | 0.51 | 0.99 | ||||||
| Gross debt/equity | x | 0.80 | 1.18 | ||||||
ETFs that hold Novartis
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Vanguard Total International Stock ETF | VXUS | 10 | 0.62% |
| Vanguard FTSE Developed Markets ETF | VEA | 7 | 0.85% |
| iShares Core MSCI EAFE ETF | IEFA | 5 | 1.06% |
| Vanguard FTSE All-World ex-US ETF | VEU | 9 | 0.68% |
| iShares MSCI EAFE ETF | EFA | 5 | 1.23% |
| Schwab International Equity ETF | SCHF | 8 | 0.91% |
| iShares Core MSCI Total International Stock ETF | IXUS | 10 | 0.62% |
| State Street SPDR Portfolio Developed World ex-US ETF | SPDW | 9 | 0.79% |
| Vanguard FTSE Europe ETF | VGK | 4 | 1.74% |
| iShares Core MSCI International Developed Markets ETF | IDEV | 6 | 0.93% |
Funds with Novartis among their ten largest holdings, largest fund first.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| Vanguard Total International Stock ETF | VXUS | 10 | 0.62% |
| Vanguard FTSE Developed Markets ETF | VEA | 7 | 0.85% |
| iShares Core MSCI EAFE ETF | IEFA | 5 | 1.06% |
| Vanguard FTSE All-World ex-US ETF | VEU | 9 | 0.68% |
| iShares MSCI EAFE ETF | EFA | 5 | 1.23% |
| Schwab International Equity ETF | SCHF | 8 | 0.91% |
| iShares Core MSCI Total International Stock ETF | IXUS | 10 | 0.62% |
| State Street SPDR Portfolio Developed World ex-US ETF | SPDW | 9 | 0.79% |
| Vanguard FTSE Europe ETF | VGK | 4 | 1.74% |
| iShares Core MSCI International Developed Markets ETF | IDEV | 6 | 0.93% |
Funds with Novartis among their ten largest holdings, largest fund first.
Based on consensus from external analysts. Not Kvantra's opinion.
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free